Fastest Growing Stocks
ARGX is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
ARGENX SE - ADR (ARGX) Stock Price & Overview
NASDAQ:ARGX • US04016X1019
Current stock price
746.42 USD
+3.3 (+0.44%)
At close:
746.42 USD
0 (0%)
After Hours:
The current stock price of ARGX is 746.42 USD. Today ARGX is up by 0.44%. In the past month the price increased by 2.51%. In the past year, price increased by 34.46%.
ARGX Key Statistics
52-Week Range510.055 - 934.62
Current ARGX stock price positioned within its 52-week range.
1-Month Range661.85 - 759.995
Current ARGX stock price positioned within its 1-month range.
- Market Cap
- 46.191B
- P/E
- 35.63
- Fwd P/E
- 24.92
- EPS (TTM)
- 20.95
- Dividend Yield
- N/A
ARGX Stock Performance
Today
+0.44%
1 Week
+7.73%
1 Month
+2.51%
3 Months
-11.14%
Longer-term
6 Months -6.70%
1 Year +34.46%
2 Years +98.78%
3 Years +92.44%
5 Years +160.34%
10 Years N/A
ARGX Stock Chart
ARGX Stock Screens
ARGX currently appears in the following ChartMill screener lists.
Revenue Growth Leaders
ARGX is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
ARGX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ARGX. When comparing the yearly performance of all stocks, ARGX turns out to be only a medium performer in the overall market: it outperformed 61.11% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ARGX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ARGX. Both the profitability and the financial health of ARGX get a neutral evaluation. Nothing too spectacular is happening here.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ARGX Earnings
On February 26, 2026 ARGX reported an EPS of 8.61 and a revenue of 1.32B. The company beat EPS expectations (28.67% surprise) and beat revenue expectations (0.3% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported$8.61
Revenue Reported1.322B
EPS Surprise 28.67%
Revenue Surprise 0.30%
ARGX Forecast & Estimates
25 analysts have analysed ARGX and the average price target is 1031.57 USD. This implies a price increase of 38.2% is expected in the next year compared to the current price of 746.42.
For the next year, analysts expect an EPS growth of 42.94% and a revenue growth 38.91% for ARGX
Analysts
Analysts84
Price Target1031.57 (38.2%)
EPS Next Y42.94%
Revenue Next Year38.91%
ARGX Groups
Sector & Classification
ARGX Financial Highlights
Over the last trailing twelve months ARGX reported a non-GAAP Earnings per Share(EPS) of 20.95. The EPS increased by 1028.32% compared to the year before.
Income Statements
Revenue(TTM)4.15B
Net Income(TTM)1.29B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.12% | ||
| ROA | 18.01% | ||
| ROE | 21.2% | ||
| Debt/Equity | 0.01 |
Chartmill High Growth Momentum
EPS Q2Q%762.37%
Sales Q2Q%73.67%
EPS 1Y (TTM)1028.32%
Revenue 1Y (TTM)89.56%
ARGX Ownership
Ownership
Inst Owners44.15%
Shares61.88M
Float61.87M
Ins Owners0.12%
Short Float %3.05%
Short Ratio5.14
ARGX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ARGX
Company Profile
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Company Info
IPO: 2014-07-10
ARGENX SE - ADR
Laarderhoogtweg 25
Amsterdam NOORD-HOLLAND 4811 AH NL
CEO: Tim Van Hauwermeiren
Employees: 1599
Phone: 31763030
ARGENX SE - ADR / ARGX FAQ
What does ARGX do?
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Can you provide the latest stock price for ARGENX SE - ADR?
The current stock price of ARGX is 746.42 USD. The price increased by 0.44% in the last trading session.
Does ARGX stock pay dividends?
ARGX does not pay a dividend.
How is the ChartMill rating for ARGENX SE - ADR?
ARGX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Where is ARGENX SE - ADR (ARGX) stock traded?
ARGX stock is listed on the Nasdaq exchange.
What is the analyst forecast for ARGX stock?
25 analysts have analysed ARGX and the average price target is 1031.57 USD. This implies a price increase of 38.2% is expected in the next year compared to the current price of 746.42.
Can you provide the growth outlook for ARGENX SE - ADR?
The Revenue of ARGENX SE - ADR (ARGX) is expected to grow by 38.91% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.